Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.
OBJECTIVE
To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH).


METHODS
Interventional case series.


METHODS
Medical records of the 2 patients were reviewed.


RESULTS
After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period.


CONCLUSIONS
Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.
Wang
Yue
Y
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA.
Gaudio
Paul A
PA
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D000069285:Infliximab; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy*; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab